Page last updated: 2024-10-25

citalopram and Chronic Disease

citalopram has been researched along with Chronic Disease in 71 studies

Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.

Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).

Research Excerpts

ExcerptRelevanceReference
"To determine whether 24 months of treatment with escitalopram improves mortality, morbidity, and mood in patients with chronic systolic heart failure and depression."9.22Effect of Escitalopram on All-Cause Mortality and Hospitalization in Patients With Heart Failure and Depression: The MOOD-HF Randomized Clinical Trial. ( Angermann, CE; Blankenberg, S; Böhm, M; Deckert, J; Edelmann, F; Ertl, G; Faller, H; Gelbrich, G; Gottwik, M; Graf, T; Gunold, H; Haass, M; Kindermann, I; Pankuweit, S; Prettin, C; Schunkert, H; Störk, S; Wachter, R, 2016)
"Escitalopram has never been demonstrated to be useful in the treatment of chronic low back pain (CLBP), while duloxetine has demonstrated analgesic effect in chronic pain states."9.14Escitalopram 20 mg versus duloxetine 60 mg for the treatment of chronic low back pain. ( Mazza, M; Mazza, O; Mazza, S; Padua, L; Pazzaglia, C, 2010)
"Participants with major depressive disorder (N = 2875) at primary and specialty care sites who received the first step treatment with citalopram in the Sequenced Treatment Alternatives to Relieve Depression study were included."9.13Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report. ( Fava, M; Khan, AY; McGrath, PJ; Miyahara, S; Morris, DW; Nierenberg, AA; Rush, AJ; Stewart, JW; Trivedi, MH; Wisniewski, SR, 2008)
"To determine the efficacy of citalopram in the treatment of chronic pelvic pain by measuring changes in pain severity, depressive symptoms and functional disability."9.13Citalopram in the treatment of women with chronic pelvic pain: an open-label trial. ( Brown, CS; Franks, AS; Ling, FW; Wan, J, 2008)
"The tricyclic antidepressant amitriptyline is the only documented and most widely used prophylactic drug for chronic tension-type headache (CTTH)."9.11Analgesic effect of amitriptyline in chronic tension-type headache is not directly related to serotonin reuptake inhibition. ( Ashina, S; Bendtsen, L; Jensen, R, 2004)
"In design 1, fatigue for subjects taking citalopram was significantly and substantially reduced when subjects were switched from placebo to citalopram, p <."9.10The effectiveness of citalopram for idiopathic chronic fatigue. ( Bentler, SE; Brake, KA; Hartz, AJ; Kelly, MW, 2003)
" The effect of the adjuvant selective serotonin reuptake inhibitor citalopram was assessed regarding the symptom dimensions of schizophrenia measured with the Positive and Negative Syndrome Scale (PANSS) and with the Hamilton Rating Scale for Depression (HRSD)."9.08Citalopram as an adjuvant in schizophrenia: further evidence for a serotonergic dimension in schizophrenia. ( Ahola, V; Lehto, H; Niemi, H; Saarijärvi, S; Salokangas, RK; Syvälahti, E; Taiminen, TJ, 1997)
"Although the tricyclic antidepressant amitriptyline is extensively used in the prophylactic treatment of chronic tension-type headache, only few studies have investigated the efficacy of this treatment and the results are contradictory."9.08A non-selective (amitriptyline), but not a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache. ( Bendtsen, L; Jensen, R; Olesen, J, 1996)
"to compare different doses of escitalopram (cipralex) in the prevention of dementia in patients with depression and moderate cognitive dysfunction associated with chronic brain ischemia."7.81[Comparison of different doses of escitalopram in the prevention of dementia in patients with depression and moderate cognitive dysfunction associated with chronic brain ischemia]. ( Zhitkova, JV, 2015)
" This study compared adherence and persistence rates among MDD patients with comorbid chronic pain-related diseases (CPD, including fibromyalgia, diabetes with neurological manifestations, osteoarthritis, low back pain, and headache) for three antidepressants: duloxetine, venlafaxine XR, and escitalopram."7.77Treatment adherence and persistence with duloxetine, venlafaxine XR, and escitalopram among patients with major depressive disorder and chronic pain-related diseases. ( Liu, X; Mullins, CD; Wang, J, 2011)
"The effects of acute, systemic administration of amitriptyline, duloxetine and mirtazapine (antidepressant drugs that variously affect extracellular noradrenaline and serotonin levels) and the selective serotonin reuptake inhibitor (SSRI) citalopram were compared in rat models of experimental pain."7.73Antinociceptive effects of the antidepressants amitriptyline, duloxetine, mirtazapine and citalopram in animal models of acute, persistent and neuropathic pain. ( Blackburn-Munro, G; Bomholt, SF; Mikkelsen, JD, 2005)
"The selective sigma2 (sigma2) ligand Lu 28-179, or 1'-[4[1-(4-fluorophenyl)-1H-indol-3-yl]-l-butyl]spiro[isobenzofuran++ +-1(3H),4'-piperidine], was studied in the chronic mild stress (CMS) model of depression."7.70The selective sigma2 ligand Lu 28-179 has an antidepressant-like profile in the rat chronic mild stress model of depression. ( Papp, M; Sánchez, C, 2000)
"Escitalopram was well tolerated, but was not more effective than placebo in the treatment of negative symptoms in patients with chronic schizophrenia."6.75Escitalopram in the treatment of negative symptoms in patients with chronic schizophrenia: a randomized double-blind placebo-controlled trial. ( Bodner, E; Iancu, I; Lowengrub, K; Piconne, AS; Tschernihovsky, E, 2010)
"Latent or manifest chronic hepatic encephalopathy (HE) symptomatology often includes affective symptoms."5.30Altered open-field behavior in experimental chronic hepatic encephalopathy after single venlafaxine and citalopram challenges. ( Andersson, G; Apelqvist, G; Bengtsson, F; Bergqvist, PB; Hindfelt, B; Wikell, C, 1999)
"To determine whether 24 months of treatment with escitalopram improves mortality, morbidity, and mood in patients with chronic systolic heart failure and depression."5.22Effect of Escitalopram on All-Cause Mortality and Hospitalization in Patients With Heart Failure and Depression: The MOOD-HF Randomized Clinical Trial. ( Angermann, CE; Blankenberg, S; Böhm, M; Deckert, J; Edelmann, F; Ertl, G; Faller, H; Gelbrich, G; Gottwik, M; Graf, T; Gunold, H; Haass, M; Kindermann, I; Pankuweit, S; Prettin, C; Schunkert, H; Störk, S; Wachter, R, 2016)
"Escitalopram has never been demonstrated to be useful in the treatment of chronic low back pain (CLBP), while duloxetine has demonstrated analgesic effect in chronic pain states."5.14Escitalopram 20 mg versus duloxetine 60 mg for the treatment of chronic low back pain. ( Mazza, M; Mazza, O; Mazza, S; Padua, L; Pazzaglia, C, 2010)
"Participants with major depressive disorder (N = 2875) at primary and specialty care sites who received the first step treatment with citalopram in the Sequenced Treatment Alternatives to Relieve Depression study were included."5.13Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report. ( Fava, M; Khan, AY; McGrath, PJ; Miyahara, S; Morris, DW; Nierenberg, AA; Rush, AJ; Stewart, JW; Trivedi, MH; Wisniewski, SR, 2008)
"To determine the efficacy of citalopram in the treatment of chronic pelvic pain by measuring changes in pain severity, depressive symptoms and functional disability."5.13Citalopram in the treatment of women with chronic pelvic pain: an open-label trial. ( Brown, CS; Franks, AS; Ling, FW; Wan, J, 2008)
"The tricyclic antidepressant amitriptyline is the only documented and most widely used prophylactic drug for chronic tension-type headache (CTTH)."5.11Analgesic effect of amitriptyline in chronic tension-type headache is not directly related to serotonin reuptake inhibition. ( Ashina, S; Bendtsen, L; Jensen, R, 2004)
"In design 1, fatigue for subjects taking citalopram was significantly and substantially reduced when subjects were switched from placebo to citalopram, p <."5.10The effectiveness of citalopram for idiopathic chronic fatigue. ( Bentler, SE; Brake, KA; Hartz, AJ; Kelly, MW, 2003)
" The effect of the adjuvant selective serotonin reuptake inhibitor citalopram was assessed regarding the symptom dimensions of schizophrenia measured with the Positive and Negative Syndrome Scale (PANSS) and with the Hamilton Rating Scale for Depression (HRSD)."5.08Citalopram as an adjuvant in schizophrenia: further evidence for a serotonergic dimension in schizophrenia. ( Ahola, V; Lehto, H; Niemi, H; Saarijärvi, S; Salokangas, RK; Syvälahti, E; Taiminen, TJ, 1997)
"Although the tricyclic antidepressant amitriptyline is extensively used in the prophylactic treatment of chronic tension-type headache, only few studies have investigated the efficacy of this treatment and the results are contradictory."5.08A non-selective (amitriptyline), but not a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache. ( Bendtsen, L; Jensen, R; Olesen, J, 1996)
"Data of 1296 outpatients with nonpsychotic depression who entered a 12-month naturalistic follow-up period after achieving remission with citalopram for up to 14 weeks were analyzed."4.31Predicting relapse from the time to remission during the acute treatment of depression: A re-analysis of the STAR*D data. ( Kubo, K; Mimura, M; Sakurai, H; Tani, H; Uchida, H; Watanabe, K, 2023)
"to compare different doses of escitalopram (cipralex) in the prevention of dementia in patients with depression and moderate cognitive dysfunction associated with chronic brain ischemia."3.81[Comparison of different doses of escitalopram in the prevention of dementia in patients with depression and moderate cognitive dysfunction associated with chronic brain ischemia]. ( Zhitkova, JV, 2015)
" This study compared adherence and persistence rates among MDD patients with comorbid chronic pain-related diseases (CPD, including fibromyalgia, diabetes with neurological manifestations, osteoarthritis, low back pain, and headache) for three antidepressants: duloxetine, venlafaxine XR, and escitalopram."3.77Treatment adherence and persistence with duloxetine, venlafaxine XR, and escitalopram among patients with major depressive disorder and chronic pain-related diseases. ( Liu, X; Mullins, CD; Wang, J, 2011)
"The purpose of this study was to analyze the antidepressant-like actions of estradiol valerate (1 or 2 mg/rat, single injection) or citalopram (5 or 10 mg/kg, chronically administered for 21 days) given independently or combined at low doses, to middle-aged ovariectomized female rats, as a model of human menopause."3.76Estradiol valerate elicits antidepressant-like effects in middle-aged female rats under chronic mild stress. ( Fernández-Guasti, A; Romano-Torres, M, 2010)
" The case presentation illustrates the role of pregabalin in successful medical management of this chronic pain disorder, as well as the management of common psychiatric morbidities associated with this condition."3.74Pregabalin-induced remission in a 62-year-old woman with a 20-year history of vulvodynia. ( Jerome, L, 2007)
"A stress-induced decrease in sucrose preference in rodents is regarded as an analog of anhedonia, a key symptom of depression."3.73Selective effects of citalopram in a mouse model of stress-induced anhedonia with a control for chronic stress. ( Bartsch, D; Dolgov, O; Gorenkova, N; Schunk, E; Strekalova, T, 2006)
"The effects of acute, systemic administration of amitriptyline, duloxetine and mirtazapine (antidepressant drugs that variously affect extracellular noradrenaline and serotonin levels) and the selective serotonin reuptake inhibitor (SSRI) citalopram were compared in rat models of experimental pain."3.73Antinociceptive effects of the antidepressants amitriptyline, duloxetine, mirtazapine and citalopram in animal models of acute, persistent and neuropathic pain. ( Blackburn-Munro, G; Bomholt, SF; Mikkelsen, JD, 2005)
" During exposure to hypoxia (10% O2 for 2 weeks), the animals received one of the specific 5-HTT inhibitors citalopram and fluoxetine (10 mg/kg/day), the selective 5-HT1B/1D receptor antagonist GR127935 (2 and 10 mg/kg/day), or the 5-HT2A receptor antagonist ketanserin (2 mg/kg/day)."3.72Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension. ( Adnot, S; Eddahibi, S; Hamon, M; Marcos, E; Nosjean, A; Pham, MH; Raffestin, B, 2003)
"The selective sigma2 (sigma2) ligand Lu 28-179, or 1'-[4[1-(4-fluorophenyl)-1H-indol-3-yl]-l-butyl]spiro[isobenzofuran++ +-1(3H),4'-piperidine], was studied in the chronic mild stress (CMS) model of depression."3.70The selective sigma2 ligand Lu 28-179 has an antidepressant-like profile in the rat chronic mild stress model of depression. ( Papp, M; Sánchez, C, 2000)
" Further studies should evaluate whether repeated dosing of SSRIs, or as combined with specific interventions, is required to elicit significant benefit of these agents on lower limb function poststroke."2.80Increased Lower Limb Spasticity but Not Strength or Function Following a Single-Dose Serotonin Reuptake Inhibitor in Chronic Stroke. ( Gourab, K; Hornby, TG; Schmit, BD, 2015)
"The co-occurrence of substance use disorder (SUD) and major depressive disorder (MDD) is common and is often thought to impair response to antidepressant therapy."2.77Effect of concurrent substance use disorder on the effectiveness of single and combination antidepressant medications for the treatment of major depression: an exploratory analysis of a single-blind randomized trial. ( Balasubramani, GK; Davis, LL; Fava, M; Gaynes, BN; Howland, RH; Pilkinton, P; Rush, AJ; Trivedi, MH; Wisniewski, SR; Zisook, S, 2012)
"Despite a substantial improvement in PTSD symptoms, there was virtually no change in BDNF levels over time."2.75Serum brain-derived neurotrophic factor predicts responses to escitalopram in chronic posttraumatic stress disorder. ( Berger, W; Lenoci, M; Marmar, CR; Mehra, A; Mellon, SH; Metzler, TJ; Neylan, TC; Otte, C; Tarasovsky, G; Wolkowitz, OM, 2010)
"Escitalopram was well tolerated, but was not more effective than placebo in the treatment of negative symptoms in patients with chronic schizophrenia."2.75Escitalopram in the treatment of negative symptoms in patients with chronic schizophrenia: a randomized double-blind placebo-controlled trial. ( Bodner, E; Iancu, I; Lowengrub, K; Piconne, AS; Tschernihovsky, E, 2010)
"Bupropion SR in the treatment of PTSD had no significant effect in the current sample."2.73A placebo-controlled trial of bupropion SR in the treatment of chronic posttraumatic stress disorder. ( Becker, ME; Beckham, JC; Bukenya, DS; Dennis, MF; Hertzberg, MA; Moore, SD, 2007)
"Methylphenidate was tapered and discontinued during weeks 9 and 10."2.71Combined treatment with methylphenidate and citalopram for accelerated response in the elderly: an open trial. ( Kim, MD; Kumar, A; Lavretsky, H; Reynolds, CF, 2003)
"Baseline measures of PTSD, depression, salivary 8 am and 4 pm cortisol, and serum interleukin-1beta (IL-1beta; pro-inflammatory) and soluble interleukin-2 receptors (IL-2R; cell-mediated immunity) were obtained for 58 PTSD and 21 control subjects."2.71Neuroimmune and cortisol changes in selective serotonin reuptake inhibitor and placebo treatment of chronic posttraumatic stress disorder. ( Hossain, A; Masters, B; Parker, DE; Ruwe, WD; Trautman, RP; Tucker, P; Wyatt, DB, 2004)
"All of the patients with primary conversion disorder had a current or previous depressive or anxiety disorder compared with 40% (N = 2) of the patients with additional somatoform diagnoses."2.71Antidepressant treatment outcomes of psychogenic movement disorder. ( Lang, AE; Voon, V, 2005)
"Escitalopram has previously been shown to be effective and well tolerated in the acute treatment of GAD."2.71Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder. ( Bose, A; Davidson, JR; Wang, Q, 2005)
" Citalopram dosing began at 20 mg/day and could be titrated to 60 mg/day."2.70Naturalistic study of the early psychiatric use of citalopram in the United States. ( Bose, A; Heydorn, WE; Rush, AJ, 2002)
" Chronic administration of amitriptyline reversed the despaired behavior induced by exposure to UCMS paradigm and, fully recovered pNF-H labeling to control values."1.46Effect of amitriptyline treatment on neurofilament-H protein in an experimental model of depression. ( Galeotti, N; Ghelardini, C; Sanna, MD, 2017)
"Escitalopram treatment significantly decreased PAI-1 levels in the serum, but not in the CSF."1.43Plasminogen Activator Inhibitor-1 in depression: Results from Animal and Clinical Studies. ( Chen, S; Jiang, H; Li, X; Liang, J; Lu, N; Yuan, Y; Yue, Y; Zhang, Z, 2016)
"Escitalopram treatment decreased anxiety-related behaviours in stressed animals, by increasing the time spent in the central part of the arena with respect to saline treated stressed animals, without affecting exploratory related behaviours."1.40Behavioural and transcriptional effects of escitalopram in the chronic escape deficit model of depression. ( Alboni, S; Benatti, C; Blom, JM; Brunello, N; Gandolfi, F; Mendlewicz, J; Tascedda, F, 2014)
"Escitalopram was associated with higher expected number of SFDs than paroxetine (86."1.35Cost-effectiveness of escitalopram for generalized anxiety disorder in Canada. ( Bereza, BG; Einarson, TR; Iskedjian, M; Le Melledo, JM; Walker, JH, 2008)
"Escitalopram (ES-CIT) is a widely used, highly specific antidepressant."1.35Effects of escitalopram on the regulation of brain-derived neurotrophic factor and nerve growth factor protein levels in a rat model of chronic stress. ( Abumaria, N; Danker-Hopfe, H; Fuchs, E; Hellweg, R; Hiemke, C; Schulte-Herbrüggen, O; Ziegler, A, 2009)
"Citalopram was generally begun at 20 mg/day and raised to 40 mg/day by weeks 2 through 4 and to 60 mg/day (final dose) by weeks 4 through 6."1.35Does the duration of index episode affect the treatment outcome of major depressive disorder? A STAR*D report. ( Alpert, JE; Fava, M; Fleck, J; Gilmer, WS; Gollan, JK; Howland, RH; Miyahara, S; Nierenberg, AA; Rush, AJ; Thase, ME; Trivedi, MH; Warden, D; Wisniewski, SR, 2008)
"Latent or manifest chronic hepatic encephalopathy (HE) symptomatology often includes affective symptoms."1.30Altered open-field behavior in experimental chronic hepatic encephalopathy after single venlafaxine and citalopram challenges. ( Andersson, G; Apelqvist, G; Bengtsson, F; Bergqvist, PB; Hindfelt, B; Wikell, C, 1999)

Research

Studies (71)

TimeframeStudies, this research(%)All Research%
pre-19901 (1.41)18.7374
1990's5 (7.04)18.2507
2000's33 (46.48)29.6817
2010's30 (42.25)24.3611
2020's2 (2.82)2.80

Authors

AuthorsStudies
Kubo, K1
Sakurai, H1
Tani, H1
Watanabe, K1
Mimura, M1
Uchida, H1
Wigner, P1
Synowiec, E1
Jóźwiak, P1
Czarny, P1
Bijak, M1
Białek, K1
Szemraj, J1
Gruca, P2
Papp, M4
Śliwiński, T1
Bausch, P1
Fangmeier, T2
Zobel, I2
Schoepf, D2
Drost, S2
Schnell, K2
Walter, H2
Berger, M2
Normann, C2
Schramm, E2
Wu, C1
Gong, WG2
Wang, YJ1
Sun, JJ1
Zhou, H1
Zhang, ZJ3
Ren, QG1
Zhong, Q1
Yu, H1
Huang, C1
Zhong, J1
Wang, H1
Xu, J1
Cheng, Y1
do Prado-Lima, PAS1
Onsten, GA1
de Oliveira, GN1
Brito, GC1
Ghilardi, IM1
de Souza, EV1
Dos Santos, PG1
Salamoni, SD1
Machado, DC1
Duarte, MMF1
Barbisan, F1
da Cruz, IBM1
Costa-Ferro, ZSM1
daCosta, JC1
Opal, MD1
Klenotich, SC1
Morais, M1
Bessa, J1
Winkle, J1
Doukas, D1
Kay, LJ1
Sousa, N1
Dulawa, SM1
Warden, D5
Trivedi, MH9
Carmody, T1
Toups, M1
Zisook, S4
Lesser, I1
Myers, A1
Kurian, KR1
Morris, D1
Rush, AJ9
Lason-Tyburkiewicz, M1
Litwa, E1
Willner, P1
Benatti, C1
Alboni, S1
Blom, JM1
Gandolfi, F1
Mendlewicz, J1
Brunello, N1
Tascedda, F1
Zhang, Y1
Wang, Y1
Wang, L1
Bai, M1
Zhang, X1
Zhu, X1
Li, XL1
Yuan, YG1
Xu, H1
Wu, D1
Geng, LY1
Wu, FF1
Tang, H1
Xu, L1
Schmidt, P1
Brakemeier, EL1
Ide, S1
Satoyoshi, H1
Minami, M1
Satoh, M1
Zhitkova, JV1
Gourab, K1
Schmit, BD1
Hornby, TG1
Angermann, CE1
Gelbrich, G1
Störk, S1
Gunold, H1
Edelmann, F1
Wachter, R1
Schunkert, H1
Graf, T1
Kindermann, I1
Haass, M1
Blankenberg, S1
Pankuweit, S1
Prettin, C1
Gottwik, M1
Böhm, M1
Faller, H1
Deckert, J1
Ertl, G1
Jiang, H1
Li, X1
Chen, S1
Lu, N1
Yue, Y1
Liang, J1
Zhang, Z1
Yuan, Y1
Sanna, MD1
Ghelardini, C1
Galeotti, N1
Lapiz-Bluhm, MD2
Soto-Piña, AE1
Hensler, JG1
Morilak, DA2
Gilmer, WS2
Gollan, JK1
Wisniewski, SR8
Howland, RH3
Miyahara, S2
Fleck, J1
Thase, ME3
Alpert, JE1
Nierenberg, AA6
Fava, M7
Lekakis, J1
Ikonomidis, I1
Papoutsi, Z1
Moutsatsou, P1
Nikolaou, M1
Parissis, J1
Kremastinos, DT1
McGrath, PJ3
Khan, AY1
Stewart, JW2
Morris, DW2
Karlsson, H1
Schulte-Herbrüggen, O1
Fuchs, E1
Abumaria, N2
Ziegler, A1
Danker-Hopfe, H1
Hiemke, C2
Hellweg, R1
Pollack, MH1
Klein, DN1
Arnow, BA1
Barkin, JL1
Dowling, F1
Kocsis, JH1
Leon, AC1
Manber, R1
Rothbaum, BO1
Masand, P1
Narasimhan, M1
Romano-Torres, M1
Fernández-Guasti, A1
Mazza, M1
Mazza, O1
Pazzaglia, C1
Padua, L1
Mazza, S1
Iancu, I1
Tschernihovsky, E1
Bodner, E1
Piconne, AS1
Lowengrub, K1
Berger, W1
Mehra, A1
Lenoci, M1
Metzler, TJ1
Otte, C1
Tarasovsky, G1
Mellon, SH1
Wolkowitz, OM1
Marmar, CR1
Neylan, TC1
Milinevskiĭ, IV1
Shabaldina, EV1
Shamova, IP1
Shabaldin, AV1
Wang, J1
Liu, X1
Mullins, CD1
Furr, A1
Sung, SC2
Haley, CL2
Chan, HN1
Balasubramani, GK3
Gaynes, BN2
Hollon, SD1
Chen, YC1
Tan, QR1
Dang, W1
Wang, HN1
Zhang, RB1
Li, ZY1
Lin, H1
Liu, R1
Davis, LL1
Pilkinton, P1
Araya-Callís, C1
Flugge, G1
Kurian, BT1
Bose, A2
Heydorn, WE1
Marcos, E1
Adnot, S1
Pham, MH1
Nosjean, A1
Raffestin, B1
Hamon, M1
Eddahibi, S1
Hartz, AJ1
Bentler, SE1
Brake, KA1
Kelly, MW1
Lavretsky, H1
Kim, MD1
Kumar, A1
Reynolds, CF1
Lavori, PW1
Sackeim, HA1
Quitkin, FM1
Kashner, TM1
Kupfer, DJ1
Rosenbaum, JF1
Alpert, J1
Biggs, MM2
Shores-Wilson, K2
Lebowitz, BD1
Ritz, L2
Niederehe, G1
Ashina, S1
Bendtsen, L2
Jensen, R2
Tucker, P1
Ruwe, WD1
Masters, B1
Parker, DE1
Hossain, A1
Trautman, RP1
Wyatt, DB1
Bomholt, SF1
Mikkelsen, JD1
Blackburn-Munro, G1
Fontenelle, LF1
Mendlowicz, MV1
Miguel, EC1
Versiani, M1
Norquist, G1
Lebowitz, B1
Voon, V1
Lang, AE1
Davidson, JR1
Wang, Q1
Strekalova, T1
Gorenkova, N1
Schunk, E1
Dolgov, O1
Bartsch, D1
Becker, ME1
Hertzberg, MA1
Moore, SD1
Dennis, MF1
Bukenya, DS1
Beckham, JC1
Jerome, L1
Boz, C1
Gazioglu, S1
Altunayoglu, V1
Hocaoglu, C1
Montross, L1
Kasckow, J1
Mohamed, S1
Palmer, BW1
Patterson, TL1
Golshan, S1
Fellows, I1
Lehman, D1
Solorzano, E1
Wang, SH1
Guo, YJ1
Teng, GJ1
Chen, BA1
Sarkar, R1
Klein, J1
Krüger, S1
Iskedjian, M1
Walker, JH1
Bereza, BG1
Le Melledo, JM1
Einarson, TR1
Brown, CS1
Franks, AS1
Wan, J1
Ling, FW1
Olesen, J1
Salokangas, RK2
Saarijärvi, S2
Taiminen, T1
Kallioniemi, H1
Lehto, H2
Niemi, H2
Tuominen, J1
Ahola, V2
Syvälahti, E2
Taiminen, TJ1
Baraczka, K1
Jankó, Z1
Vargha, K1
Márkus, H1
Apelqvist, G1
Wikell, C1
Hindfelt, B1
Bergqvist, PB1
Andersson, G1
Bengtsson, F1
Sánchez, C2
Iakovlev, VA1
Belinskiĭ, AV1
Dorovskikh, IV1
Nalepa, I1
Antkiewicz-Michaluk, L1
Larsen, JJ1
Arnt, J1

Clinical Trials (11)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Combining Medications to Enhance Depression Outcomes[NCT00590863]Phase 4665 participants (Actual)Interventional2008-03-31Completed
Enhanced Motor Recovery Using Serotonergic Agents in Stroke[NCT01751854]Phase 130 participants (Actual)Interventional2004-12-31Completed
Sequenced Treatment Alternatives to Relieve Depression[NCT00021528]Phase 44,000 participants Interventional2001-07-31Completed
Melancholic Depression and Insomnia as Predictors of Response to Quetiapine in Patients With Major Depression[NCT03207438]Phase 41,790 participants (Actual)Interventional2006-04-30Completed
Phase III Open Study of High Dose Escitalopram for the Treatment of Obsessive-Compulsive Disorder in Adults[NCT00305500]Phase 3100 participants Interventional2006-03-31Completed
Digital Interventions as an Add-on Tool in Generalized Anxiety Disorder Treatment: A Randomized Clinical Trial[NCT05375851]60 participants (Anticipated)Interventional2022-05-01Recruiting
Dallas 2K: A Natural History Study of Depression[NCT02919280]2,000 participants (Anticipated)Observational2016-09-30Recruiting
Double-Blind, Placebo-Controlled, Randomized Trial of Adjunctive Lisdexamfetamine Dimesylate in Residual Symptoms of Major Depressive Disorder Partially Responsive to Selective Serotonin or Norepinephrine Reuptake Inhibitor Monotherapy[NCT01148979]Phase 435 participants (Actual)Interventional2010-09-30Completed
Evaluation of Schemes of Administration of Intravenous Ketamine in Treatment-resistant Depression: Clinical-neuroimaging Correlation[NCT03742557]Phase 330 participants (Anticipated)Interventional2018-10-01Recruiting
Conscious Dying/Conscious Living: Ketamine-Assisted Psychotherapy (KAP) for Patients at End of Life-A Pilot Study for Palliative and Hospice Care[NCT05214417]Phase 2120 participants (Anticipated)Interventional2022-05-01Not yet recruiting
Subanesthetic Sevoflurane for Treatment-Resistant Depression: A Proof-of-Concept Trial[NCT05008939]15 participants (Anticipated)Interventional2021-08-31Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Quality of Life Inventory

The Quality of Life Inventory (QOLI) is a 32-item comprehensive self-report of satisfaction in 16 areas of life, such as love, work, and health. Each area is rated in terms of satisfaction and the relationship of that area to overall quality of life. It yields an overall raw score and satisfaction ratings for the 16 individual areas of life. The QOLI raw score is an average of weighted satisfaction ratings computed only over areas of life judged to be Important or Extremely Important to the respondent. Higher scores indicate higher reported quality of life. (NCT00590863)
Timeframe: Measured at Month 7

Interventionunits on a scale (Mean)
Escitalopram + Bupropion SR0.6
Venlafaxine XR + Mirtazapine0.4
Escitalopram + Placebo0.4

Quick Inventory of Depressive Symptoms

Percentage of patients that achieve remission, as defined as QIDS total score below 6 for last 2 study visits. QIDS depression scores range from 0 (normal) to 27 (very severe). (NCT00590863)
Timeframe: Measured at Month 7

Interventionpercentage of participants (Number)
Escitalopram + Bupropion SR46.6
Venlafaxine XR + Mirtazapine41.8
Escitalopram + Placebo46.0

MADRS Response Rates

Defined as a 50% score reduction from baseline. (NCT03207438)
Timeframe: Day 4 - Week 6

,,,
InterventionParticipants (Count of Participants)
Day 4Week 1Week 2Week 4Week 6
Placebo 1 - Insomnia612314445
Placebo 1 - No Insomnia01185
Quetiapine XR 50mg - Insomnia826425964
Quetiapine XR 50mg - No Insomnia03859

Modified MADRS Response Rate

Calculated without Item 4 (reduced sleep). (NCT03207438)
Timeframe: Day 4 - Week 6

,
InterventionParticipants (Count of Participants)
Day 4Week 1Week 2Week 4Week 6
Placebo 1611284951
Quetiapine XR 50mg622445766

Modified MADRS Response Rates

50% score reduction from baseline calculated without Item 4 (reduced sleep). (NCT03207438)
Timeframe: 1 - 6 weeks

,,,
InterventionParticipants (Count of Participants)
Week 1Week 2Week 4Week 6
Placebo 2 - Melancholic Depression26456164
Placebo 2 - Nonmelancholic Depression46100136176
Quetiapine XR 150-300mg - Melancholic Depression5390124132
Quetiapine XR 150-300mg - Nonmelancholic Depression68179231260

Number of Participants With 50 Percent Or Greater Reduction in the MADRS Score Over Time for the Quetiapine XR 150-300mg and Placebo 2 Arms/Groups Stratified by Depression Type (Melancholic vs. Nonmelancholic)

MADRS is the Montgomery-Asberg Depression Rating Scale. Total scores on this scale range from 0-60. However the response variable is binary coded (0 = No Response, 1 = Response). (NCT03207438)
Timeframe: 1 - 6 weeks

,,,
InterventionParticipants (Count of Participants)
Week 1Week 2Week 4Week 6
Placebo 2 - Melancholic Depression28416264
Placebo 2 - Nonmelancholic Depression47100136174
Quetiapine XR 150-300mg - Melancholic Depression63105124141
Quetiapine XR 150-300mg - Nonmelancholic Depression86195251274

Change From Baseline in the Dysphoric Apathy/Retardation Sub-factor (MDAR) of Montgomery-Asberg Depression Rating Scale (MADRS) at 4 Weeks.

The Montgomery-Asberg Depression Rating Scale Dysphoric Apathy Retardation subfactor (MDAR) is a 5-item subscale of the clinician-administered 10-item Montgomery-Asberg Depression Rating Scale (MADRS). MDAR score can range from 0-30 with a higher score representing a greater severity of depressive symptoms. (NCT01148979)
Timeframe: Baseline to 4 weeks of treatment

,
Interventionscores on a scale (Mean)
Baseline Mean MDAR scoreWeek 4 Mean MDAR scoreChange from BL in mean MDAR score
Lisdexamfetamine Dimesylate (Vyvanse)13.466.36-7.08
Placebo Adjunct12.579.08-3.49

Reviews

2 reviews available for citalopram and Chronic Disease

ArticleYear
Refractory generalized anxiety disorder.
    The Journal of clinical psychiatry, 2009, Volume: 70 Suppl 2

    Topics: Anti-Anxiety Agents; Anticonvulsants; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Anxiet

2009
Update on partial response in depression.
    The Journal of clinical psychiatry, 2009, Volume: 70 Suppl 6

    Topics: Antidepressive Agents; Antipsychotic Agents; Anxiety Disorders; Chronic Disease; Citalopram; Comorbi

2009

Trials

32 trials available for citalopram and Chronic Disease

ArticleYear
The impact of childhood maltreatment on the differential efficacy of CBASP versus escitalopram in patients with chronic depression: A secondary analysis.
    Clinical psychology & psychotherapy, 2017, Volume: 24, Issue:5

    Topics: Adult; Antidepressive Agents, Second-Generation; Child; Child Abuse; Chronic Disease; Citalopram; Co

2017
Adherence to antidepressant combinations and monotherapy for major depressive disorder: a CO-MED report of measurement-based care.
    Journal of psychiatric practice, 2014, Volume: 20, Issue:2

    Topics: Adult; Antidepressive Agents; Bupropion; Chronic Disease; Citalopram; Cyclohexanols; Depressive Diso

2014
Cognitive Behavioral Analysis System of Psychotherapy versus Escitalopram in Chronic Major Depression.
    Psychotherapy and psychosomatics, 2015, Volume: 84, Issue:4

    Topics: Adult; Antidepressive Agents, Second-Generation; Chronic Disease; Citalopram; Depressive Disorder, M

2015
Increased Lower Limb Spasticity but Not Strength or Function Following a Single-Dose Serotonin Reuptake Inhibitor in Chronic Stroke.
    Archives of physical medicine and rehabilitation, 2015, Volume: 96, Issue:12

    Topics: Aged; Ankle; Chronic Disease; Citalopram; Cross-Over Studies; Double-Blind Method; Female; Hemiplegi

2015
Effect of Escitalopram on All-Cause Mortality and Hospitalization in Patients With Heart Failure and Depression: The MOOD-HF Randomized Clinical Trial.
    JAMA, 2016, Jun-28, Volume: 315, Issue:24

    Topics: Affect; Aged; Antidepressive Agents, Second-Generation; Chronic Disease; Citalopram; Depression; Dru

2016
Selective serotonin re-uptake inhibitors decrease the cytokine-induced endothelial adhesion molecule expression, the endothelial adhesiveness to monocytes and the circulating levels of vascular adhesion molecules.
    International journal of cardiology, 2010, Mar-04, Volume: 139, Issue:2

    Topics: Adult; Aged; Aorta; Cell Adhesion; Cell Survival; Chronic Disease; Citalopram; Depression; Endotheli

2010
Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report.
    The Journal of clinical psychiatry, 2008, Volume: 69, Issue:12

    Topics: Adolescent; Adult; Aged; Ambulatory Care; Antidepressive Agents, Second-Generation; Chronic Disease;

2008
Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report.
    The Journal of clinical psychiatry, 2008, Volume: 69, Issue:12

    Topics: Adolescent; Adult; Aged; Ambulatory Care; Antidepressive Agents, Second-Generation; Chronic Disease;

2008
Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report.
    The Journal of clinical psychiatry, 2008, Volume: 69, Issue:12

    Topics: Adolescent; Adult; Aged; Ambulatory Care; Antidepressive Agents, Second-Generation; Chronic Disease;

2008
Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report.
    The Journal of clinical psychiatry, 2008, Volume: 69, Issue:12

    Topics: Adolescent; Adult; Aged; Ambulatory Care; Antidepressive Agents, Second-Generation; Chronic Disease;

2008
Escitalopram 20 mg versus duloxetine 60 mg for the treatment of chronic low back pain.
    Expert opinion on pharmacotherapy, 2010, Volume: 11, Issue:7

    Topics: Adult; Aged; Chronic Disease; Citalopram; Duloxetine Hydrochloride; Female; Health Surveys; Humans;

2010
Escitalopram in the treatment of negative symptoms in patients with chronic schizophrenia: a randomized double-blind placebo-controlled trial.
    Psychiatry research, 2010, Aug-30, Volume: 179, Issue:1

    Topics: Adult; Chronic Disease; Citalopram; Double-Blind Method; Drug Administration Schedule; Female; Human

2010
Serum brain-derived neurotrophic factor predicts responses to escitalopram in chronic posttraumatic stress disorder.
    Progress in neuro-psychopharmacology & biological psychiatry, 2010, Oct-01, Volume: 34, Issue:7

    Topics: Adult; Antidepressive Agents, Second-Generation; Brain-Derived Neurotrophic Factor; Chronic Disease;

2010
[The use of the antidepressant citalopran for the treatment of chronic pharyngitis and pharyngeal neurosis].
    Vestnik otorinolaringologii, 2011, Issue:2

    Topics: Adult; Antidepressive Agents, Second-Generation; Chronic Disease; Citalopram; Dose-Response Relation

2011
Is prior course of illness relevant to acute or longer-term outcomes in depressed out-patients? A STAR*D report.
    Psychological medicine, 2012, Volume: 42, Issue:6

    Topics: Adolescent; Adult; Aged; Analysis of Variance; Antidepressive Agents, Second-Generation; Chronic Dis

2012
Effect of concurrent substance use disorder on the effectiveness of single and combination antidepressant medications for the treatment of major depression: an exploratory analysis of a single-blind randomized trial.
    Depression and anxiety, 2012, Volume: 29, Issue:2

    Topics: Adolescent; Antidepressive Agents; Bupropion; Chronic Disease; Citalopram; Cyclohexanols; Depressive

2012
The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations.
    The Journal of clinical psychiatry, 2012, Volume: 73, Issue:7

    Topics: Adolescent; Adult; Aged; Antidepressive Agents; Bupropion; Chronic Disease; Citalopram; Comorbidity;

2012
Naturalistic study of the early psychiatric use of citalopram in the United States.
    Depression and anxiety, 2002, Volume: 16, Issue:3

    Topics: Chronic Disease; Citalopram; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Prospect

2002
The effectiveness of citalopram for idiopathic chronic fatigue.
    The Journal of clinical psychiatry, 2003, Volume: 64, Issue:8

    Topics: Adult; Aged; Chronic Disease; Citalopram; Drug Administration Schedule; Fatigue; Fatigue Syndrome, C

2003
Combined treatment with methylphenidate and citalopram for accelerated response in the elderly: an open trial.
    The Journal of clinical psychiatry, 2003, Volume: 64, Issue:12

    Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Central Nervous System Stimulants

2003
Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design.
    Controlled clinical trials, 2004, Volume: 25, Issue:1

    Topics: Adolescent; Adult; Aged; Antidepressive Agents; Chronic Disease; Citalopram; Clinical Protocols; Cog

2004
Analgesic effect of amitriptyline in chronic tension-type headache is not directly related to serotonin reuptake inhibition.
    Pain, 2004, Volume: 108, Issue:1-2

    Topics: Adolescent; Adult; Amitriptyline; Analgesics, Non-Narcotic; Blood Platelets; Chronic Disease; Citalo

2004
Neuroimmune and cortisol changes in selective serotonin reuptake inhibitor and placebo treatment of chronic posttraumatic stress disorder.
    Biological psychiatry, 2004, Jul-15, Volume: 56, Issue:2

    Topics: Adult; Chronic Disease; Circadian Rhythm; Citalopram; Double-Blind Method; Female; Humans; Hydrocort

2004
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    The American journal of psychiatry, 2006, Volume: 163, Issue:1

    Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D

2006
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    The American journal of psychiatry, 2006, Volume: 163, Issue:1

    Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D

2006
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    The American journal of psychiatry, 2006, Volume: 163, Issue:1

    Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D

2006
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    The American journal of psychiatry, 2006, Volume: 163, Issue:1

    Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D

2006
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    The American journal of psychiatry, 2006, Volume: 163, Issue:1

    Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D

2006
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    The American journal of psychiatry, 2006, Volume: 163, Issue:1

    Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D

2006
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    The American journal of psychiatry, 2006, Volume: 163, Issue:1

    Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D

2006
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    The American journal of psychiatry, 2006, Volume: 163, Issue:1

    Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D

2006
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    The American journal of psychiatry, 2006, Volume: 163, Issue:1

    Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D

2006
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    The American journal of psychiatry, 2006, Volume: 163, Issue:1

    Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D

2006
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    The American journal of psychiatry, 2006, Volume: 163, Issue:1

    Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D

2006
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    The American journal of psychiatry, 2006, Volume: 163, Issue:1

    Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D

2006
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    The American journal of psychiatry, 2006, Volume: 163, Issue:1

    Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D

2006
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    The American journal of psychiatry, 2006, Volume: 163, Issue:1

    Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D

2006
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    The American journal of psychiatry, 2006, Volume: 163, Issue:1

    Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D

2006
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    The American journal of psychiatry, 2006, Volume: 163, Issue:1

    Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D

2006
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    The American journal of psychiatry, 2006, Volume: 163, Issue:1

    Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D

2006
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    The American journal of psychiatry, 2006, Volume: 163, Issue:1

    Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D

2006
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    The American journal of psychiatry, 2006, Volume: 163, Issue:1

    Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D

2006
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    The American journal of psychiatry, 2006, Volume: 163, Issue:1

    Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D

2006
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    The American journal of psychiatry, 2006, Volume: 163, Issue:1

    Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D

2006
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    The American journal of psychiatry, 2006, Volume: 163, Issue:1

    Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D

2006
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    The American journal of psychiatry, 2006, Volume: 163, Issue:1

    Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D

2006
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    The American journal of psychiatry, 2006, Volume: 163, Issue:1

    Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D

2006
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    The American journal of psychiatry, 2006, Volume: 163, Issue:1

    Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D

2006
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    The American journal of psychiatry, 2006, Volume: 163, Issue:1

    Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D

2006
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    The American journal of psychiatry, 2006, Volume: 163, Issue:1

    Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D

2006
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    The American journal of psychiatry, 2006, Volume: 163, Issue:1

    Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D

2006
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    The American journal of psychiatry, 2006, Volume: 163, Issue:1

    Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D

2006
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    The American journal of psychiatry, 2006, Volume: 163, Issue:1

    Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D

2006
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    The American journal of psychiatry, 2006, Volume: 163, Issue:1

    Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D

2006
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    The American journal of psychiatry, 2006, Volume: 163, Issue:1

    Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D

2006
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    The American journal of psychiatry, 2006, Volume: 163, Issue:1

    Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D

2006
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    The American journal of psychiatry, 2006, Volume: 163, Issue:1

    Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D

2006
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    The American journal of psychiatry, 2006, Volume: 163, Issue:1

    Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D

2006
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    The American journal of psychiatry, 2006, Volume: 163, Issue:1

    Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D

2006
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    The American journal of psychiatry, 2006, Volume: 163, Issue:1

    Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D

2006
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    The American journal of psychiatry, 2006, Volume: 163, Issue:1

    Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D

2006
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    The American journal of psychiatry, 2006, Volume: 163, Issue:1

    Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D

2006
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    The American journal of psychiatry, 2006, Volume: 163, Issue:1

    Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D

2006
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    The American journal of psychiatry, 2006, Volume: 163, Issue:1

    Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D

2006
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    The American journal of psychiatry, 2006, Volume: 163, Issue:1

    Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D

2006
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    The American journal of psychiatry, 2006, Volume: 163, Issue:1

    Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D

2006
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    The American journal of psychiatry, 2006, Volume: 163, Issue:1

    Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D

2006
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    The American journal of psychiatry, 2006, Volume: 163, Issue:1

    Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D

2006
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    The American journal of psychiatry, 2006, Volume: 163, Issue:1

    Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D

2006
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    The American journal of psychiatry, 2006, Volume: 163, Issue:1

    Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D

2006
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    The American journal of psychiatry, 2006, Volume: 163, Issue:1

    Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D

2006
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    The American journal of psychiatry, 2006, Volume: 163, Issue:1

    Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D

2006
Antidepressant treatment outcomes of psychogenic movement disorder.
    The Journal of clinical psychiatry, 2005, Volume: 66, Issue:12

    Topics: Adult; Ambulatory Care; Anxiety Disorders; Chronic Disease; Citalopram; Combined Modality Therapy; C

2005
Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder.
    The Journal of clinical psychiatry, 2005, Volume: 66, Issue:11

    Topics: Adult; Ambulatory Care; Anxiety Disorders; Chronic Disease; Citalopram; Diagnostic and Statistical M

2005
A placebo-controlled trial of bupropion SR in the treatment of chronic posttraumatic stress disorder.
    Journal of clinical psychopharmacology, 2007, Volume: 27, Issue:2

    Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Attention; Bupropion; Chronic

2007
Effect of serotonergic antidepressant therapy on temperament and character scales in patients with chronic tension-type headache.
    Psychiatry and clinical neurosciences, 2007, Volume: 61, Issue:5

    Topics: Adult; Character; Chronic Disease; Citalopram; Female; Fluoxetine; Harm Reduction; Humans; Internal-

2007
Subsyndromal depressive symptoms in middle-aged and older persons with schizophrenia.
    The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2007, Volume: 15, Issue:12

    Topics: Age Factors; Chronic Disease; Citalopram; Comorbidity; Depression; Depressive Disorder, Major; Doubl

2007
Citalopram in the treatment of women with chronic pelvic pain: an open-label trial.
    The Journal of reproductive medicine, 2008, Volume: 53, Issue:3

    Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Chronic Disease; Citalopram; Depression

2008
A non-selective (amitriptyline), but not a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache.
    Journal of neurology, neurosurgery, and psychiatry, 1996, Volume: 61, Issue:3

    Topics: Adolescent; Adult; Amitriptyline; Animals; Antidepressive Agents, Tricyclic; Chronic Disease; Citalo

1996
Citalopram as an adjuvant in chronic schizophrenia: a double-blind placebo-controlled study.
    Acta psychiatrica Scandinavica, 1996, Volume: 94, Issue:3

    Topics: Adolescent; Adult; Antipsychotic Agents; Chronic Disease; Citalopram; Dose-Response Relationship, Dr

1996
Citalopram as an adjuvant in schizophrenia: further evidence for a serotonergic dimension in schizophrenia.
    International clinical psychopharmacology, 1997, Volume: 12, Issue:1

    Topics: Adult; Chronic Disease; Citalopram; Double-Blind Method; Humans; Psychiatric Status Rating Scales; S

1997
[Clinical experiences with the analgesic effects of citalopram].
    Orvosi hetilap, 1997, Oct-12, Volume: 138, Issue:41

    Topics: Analgesics; Antidepressive Agents, Second-Generation; Chronic Disease; Citalopram; Fibromyalgia; Hum

1997
[A trial of treating depressive states with cipramil].
    Voenno-meditsinskii zhurnal, 2000, Volume: 321, Issue:6

    Topics: Adult; Antidepressive Agents, Second-Generation; Chronic Disease; Citalopram; Depressive Disorder; H

2000

Other Studies

37 other studies available for citalopram and Chronic Disease

ArticleYear
Predicting relapse from the time to remission during the acute treatment of depression: A re-analysis of the STAR*D data.
    Journal of affective disorders, 2023, 01-01, Volume: 320

    Topics: Chronic Disease; Citalopram; Depression; Depressive Disorder, Major; Humans; Recurrence; Treatment O

2023
The Effect of Chronic Mild Stress and Escitalopram on the Expression and Methylation Levels of Genes Involved in the Oxidative and Nitrosative Stresses as Well as Tryptophan Catabolites Pathway in the Blood and Brain Structures.
    International journal of molecular sciences, 2020, Dec-22, Volume: 22, Issue:1

    Topics: Animals; Antidepressive Agents, Second-Generation; Brain; Catalase; Chronic Disease; Citalopram; Dep

2020
Escitalopram alleviates stress-induced Alzheimer's disease-like tau pathologies and cognitive deficits by reducing hypothalamic-pituitary-adrenal axis reactivity and insulin/GSK-3β signal pathway activity.
    Neurobiology of aging, 2018, Volume: 67

    Topics: Alzheimer Disease; Animals; Antidepressive Agents, Second-Generation; Chronic Disease; Citalopram; C

2018
FCPR16, a novel phosphodiesterase 4 inhibitor, produces an antidepressant-like effect in mice exposed to chronic unpredictable mild stress.
    Progress in neuro-psychopharmacology & biological psychiatry, 2019, 03-02, Volume: 90

    Topics: Animals; Antidepressive Agents; Benzamides; Cerebral Cortex; Chronic Disease; Citalopram; Cyclic AMP

2019
The antidepressant effect of bone marrow mononuclear cell transplantation in chronic stress.
    Journal of psychopharmacology (Oxford, England), 2019, Volume: 33, Issue:5

    Topics: Animals; Antidepressive Agents; Behavior, Animal; Bone Marrow Transplantation; Chronic Disease; Cita

2019
Serotonin 2C receptor antagonists induce fast-onset antidepressant effects.
    Molecular psychiatry, 2014, Volume: 19, Issue:10

    Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Chronic Disease; Citalopram; Cycl

2014
Effects of chronic mild stress on the development of drug dependence in rats.
    Behavioural pharmacology, 2014, Volume: 25, Issue:5-6

    Topics: Animals; Chronic Disease; Citalopram; Depressive Disorder; Diazepam; Disease Models, Animal; Flumaze

2014
Behavioural and transcriptional effects of escitalopram in the chronic escape deficit model of depression.
    Behavioural brain research, 2014, Oct-01, Volume: 272

    Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Body Weight; Chronic Disease; Citalopram

2014
Dopamine Receptor D2 and Associated microRNAs Are Involved in Stress Susceptibility and Resistance to Escitalopram Treatment.
    The international journal of neuropsychopharmacology, 2015, Mar-03, Volume: 18, Issue:8

    Topics: Animals; Antidepressive Agents, Second-Generation; Chronic Disease; Citalopram; Corpus Striatum; Dep

2015
Changed Synaptic Plasticity in Neural Circuits of Depressive-Like and Escitalopram-Treated Rats.
    The international journal of neuropsychopharmacology, 2015, Apr-21, Volume: 18, Issue:10

    Topics: Animals; Antidepressive Agents; Blotting, Western; Body Weight; Brain; Chronic Disease; Citalopram;

2015
Amelioration of the reduced antinociceptive effect of morphine in the unpredictable chronic mild stress model mice by noradrenalin but not serotonin reuptake inhibitors.
    Molecular pain, 2015, Aug-11, Volume: 11

    Topics: Analgesics; Animals; Chronic Disease; Citalopram; Disease Models, Animal; Male; Maprotiline; Mice, I

2015
[Comparison of different doses of escitalopram in the prevention of dementia in patients with depression and moderate cognitive dysfunction associated with chronic brain ischemia].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2015, Volume: 115, Issue:8

    Topics: Aged; Antidepressive Agents, Second-Generation; Brain Ischemia; Chronic Disease; Citalopram; Cogniti

2015
Plasminogen Activator Inhibitor-1 in depression: Results from Animal and Clinical Studies.
    Scientific reports, 2016, 07-26, Volume: 6

    Topics: Animals; Behavior, Animal; Body Weight; Case-Control Studies; Chronic Disease; Citalopram; Depressio

2016
Effect of amitriptyline treatment on neurofilament-H protein in an experimental model of depression.
    Brain research bulletin, 2017, Volume: 128

    Topics: Acute Disease; Amitriptyline; Animals; Antidepressive Agents, Tricyclic; CA3 Region, Hippocampal; Ch

2017
Chronic intermittent cold stress and serotonin depletion induce deficits of reversal learning in an attentional set-shifting test in rats.
    Psychopharmacology, 2009, Volume: 202, Issue:1-3

    Topics: Animals; Attention; Chronic Disease; Citalopram; Cold Temperature; Discrimination Learning; Fencloni

2009
Does the duration of index episode affect the treatment outcome of major depressive disorder? A STAR*D report.
    The Journal of clinical psychiatry, 2008, Volume: 69, Issue:8

    Topics: Adult; Chronic Disease; Citalopram; Demography; Depressive Disorder, Major; Diagnostic and Statistic

2008
Remission in depression--is it a realistic goal?
    Nordic journal of psychiatry, 2008, Volume: 62, Issue:6

    Topics: Antidepressive Agents; Chronic Disease; Citalopram; Cognitive Behavioral Therapy; Combined Modality

2008
Effects of escitalopram on the regulation of brain-derived neurotrophic factor and nerve growth factor protein levels in a rat model of chronic stress.
    Journal of neuroscience research, 2009, Aug-15, Volume: 87, Issue:11

    Topics: Adrenal Glands; Animals; Antidepressive Agents, Second-Generation; Body Weight; Brain; Brain-Derived

2009
Early adversity in chronic depression: clinical correlates and response to pharmacotherapy.
    Depression and anxiety, 2009, Volume: 26, Issue:8

    Topics: Adolescent; Adult; Age of Onset; Aged; Algorithms; Antidepressive Agents; Anxiety Disorders; Bupropi

2009
Major depressive disorder and medical illness: STAR*D outcomes.
    Current psychiatry reports, 2006, Volume: 8, Issue:3

    Topics: Adult; Antidepressive Agents, Second-Generation; Chronic Disease; Citalopram; Comorbidity; Cross-Sec

2006
Estradiol valerate elicits antidepressant-like effects in middle-aged female rats under chronic mild stress.
    Behavioural pharmacology, 2010, Volume: 21, Issue:2

    Topics: Aging; Animals; Antidepressive Agents; Chronic Disease; Citalopram; Conditioning, Operant; Depressio

2010
Treatment adherence and persistence with duloxetine, venlafaxine XR, and escitalopram among patients with major depressive disorder and chronic pain-related diseases.
    Current medical research and opinion, 2011, Volume: 27, Issue:7

    Topics: Adolescent; Adult; Algorithms; Antidepressive Agents; Chronic Disease; Citalopram; Cyclohexanols; De

2011
5-HT2A receptors in the orbitofrontal cortex facilitate reversal learning and contribute to the beneficial cognitive effects of chronic citalopram treatment in rats.
    The international journal of neuropsychopharmacology, 2012, Volume: 15, Issue:9

    Topics: 2-Hydroxypropyl-beta-cyclodextrin; Animals; Attention; beta-Cyclodextrins; Chronic Disease; Citalopr

2012
The effect of citalopram on chronic stress-induced depressive-like behavior in rats through GSK3β/β-catenin activation in the medial prefrontal cortex.
    Brain research bulletin, 2012, Jul-01, Volume: 88, Issue:4

    Topics: Animals; Antidepressive Agents; Behavior, Animal; beta Catenin; Blotting, Western; Chronic Disease;

2012
Chronic psychosocial stress and citalopram modulate the expression of the glial proteins GFAP and NDRG2 in the hippocampus.
    Psychopharmacology, 2012, Volume: 224, Issue:1

    Topics: Animals; Antidepressive Agents, Second-Generation; Astrocytes; Behavior, Animal; Chronic Disease; Ci

2012
Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension.
    American journal of respiratory and critical care medicine, 2003, Aug-15, Volume: 168, Issue:4

    Topics: Analysis of Variance; Animals; Carrier Proteins; Chronic Disease; Citalopram; Disease Models, Animal

2003
Antinociceptive effects of the antidepressants amitriptyline, duloxetine, mirtazapine and citalopram in animal models of acute, persistent and neuropathic pain.
    Neuropharmacology, 2005, Volume: 48, Issue:2

    Topics: Acute Disease; Amitriptyline; Analgesics; Animals; Antidepressive Agents; Chronic Disease; Citalopra

2005
Citalopram plus reboxetine in treatment-resistant obsessive-compulsive disorder.
    The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2005, Volume: 6, Issue:1

    Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents, Second-Generation; Chronic Disease; Cita

2005
Selective effects of citalopram in a mouse model of stress-induced anhedonia with a control for chronic stress.
    Behavioural pharmacology, 2006, Volume: 17, Issue:3

    Topics: Animals; Body Weight; Chronic Disease; Citalopram; Depression; Drinking; Hindlimb Suspension; Immers

2006
Pregabalin-induced remission in a 62-year-old woman with a 20-year history of vulvodynia.
    Pain research & management, 2007,Autumn, Volume: 12, Issue:3

    Topics: Amitriptyline; Analgesics; Anti-Ulcer Agents; Anticoagulants; Antidepressive Agents; Anxiety; Cardio

2007
Hippocampal neurogenesis and behavioural studies on adult ischemic rat response to chronic mild stress.
    Behavioural brain research, 2008, May-16, Volume: 189, Issue:1

    Topics: Adaptation, Physiological; Adaptation, Psychological; Animals; Antidepressive Agents, Second-Generat

2008
Aripiprazole augmentation in treatment-refractory obsessive-compulsive disorder.
    Psychopharmacology, 2008, Volume: 197, Issue:4

    Topics: Antipsychotic Agents; Aripiprazole; Chronic Disease; Citalopram; Drug Therapy, Combination; Female;

2008
Cost-effectiveness of escitalopram for generalized anxiety disorder in Canada.
    Current medical research and opinion, 2008, Volume: 24, Issue:5

    Topics: Adolescent; Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Anxiety Disorders

2008
Altered open-field behavior in experimental chronic hepatic encephalopathy after single venlafaxine and citalopram challenges.
    Psychopharmacology, 1999, Volume: 143, Issue:4

    Topics: Analysis of Variance; Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Chronic D

1999
The selective sigma2 ligand Lu 28-179 has an antidepressant-like profile in the rat chronic mild stress model of depression.
    Behavioural pharmacology, 2000, Volume: 11, Issue:2

    Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricy

2000
Behavioural and biochemical studies of citalopram and WAY 100635 in rat chronic mild stress model.
    Pharmacology, biochemistry, and behavior, 2002, Volume: 72, Issue:1-2

    Topics: Animals; Cerebral Cortex; Chronic Disease; Citalopram; Disease Models, Animal; Drug Therapy, Combina

2002
Reduction in locomotor activity of arthritic rats as parameter for chronic pain: effect of morphine, acetylsalicylic acid and citalopram.
    Acta pharmacologica et toxicologica, 1985, Volume: 57, Issue:5

    Topics: Animals; Arthritis; Arthritis, Experimental; Aspirin; Chronic Disease; Citalopram; Exploratory Behav

1985